These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3960016)

  • 1. Impaired extrarenal disposal of an acute oral potassium load in patients with endstage renal disease on chronic hemodialysis.
    Fernandez J; Oster JR; Perez GO
    Miner Electrolyte Metab; 1986; 12(2):125-9. PubMed ID: 3960016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-adrenergic-mediated extrarenal potassium disposal in patients with end-stage renal disease: effect of propranolol.
    Yang WC; Huang TP; Ho LT; Chung HM; Chan YL; Batlle DC
    Miner Electrolyte Metab; 1986; 12(3):186-93. PubMed ID: 2873504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a simultaneous potassium and carbohydrate load on extrarenal K homeostasis in end-stage renal failure.
    Alvo M; Krsulovic P; Fernández V; Espinoza AM; Escobar M; Marusic ET
    Nephron; 1989; 53(2):133-7. PubMed ID: 2682302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potassium homeostasis in liver cirrhosis.
    Decaux G; Soupart A; Cauchie P; Delwiche F
    Arch Intern Med; 1988 Mar; 148(3):547-8. PubMed ID: 3277570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose modulation of the disposal of an acute potassium load in patients with end-stage renal disease.
    Allon M; Dansby L; Shanklin N
    Am J Med; 1993 May; 94(5):475-482. PubMed ID: 8498392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
    Alcázar Arroyo R
    Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adrenergic modulation of extrarenal potassium disposal.
    Rosa RM; Silva P; Young JB; Landsberg L; Brown RS; Rowe JW; Epstein FH
    N Engl J Med; 1980 Feb; 302(8):431-4. PubMed ID: 6101508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal failure, parathyroid hormone and extrarenal disposal of potassium.
    Massry SG
    Miner Electrolyte Metab; 1990; 16(1):77-81. PubMed ID: 2182997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potassium homeostasis in chronic diabetes mellitus.
    Perez GO; Lespier L; Knowles R; Oster JR; Vaamonde CA
    Arch Intern Med; 1977 Aug; 137(8):1018-22. PubMed ID: 327962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of aminophylline and insulin-dextrose infusions in acute therapy of hyperkalemia in end-stage renal disease patients.
    Mahajan SK; Mangla M; Kishore K
    J Assoc Physicians India; 2001 Nov; 49():1082-5. PubMed ID: 11868861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oral glucose administration on serum potassium concentration in hemodialysis patients.
    Muto S; Sebata K; Watanabe H; Shoji F; Yamamoto Y; Ohashi M; Yamada T; Matsumoto H; Mukouyama T; Yonekura T; Namiki S; Kusano E
    Am J Kidney Dis; 2005 Oct; 46(4):697-705. PubMed ID: 16183425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease.
    Tuzcu A; Bahceci M; Yilmaz ME; Turgut C; Kara IH
    Saudi Med J; 2005 May; 26(5):786-91. PubMed ID: 15951871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients.
    Kaisar MO; Wiggins KJ; Sturtevant JM; Hawley CM; Campbell SB; Isbel NM; Mudge DW; Bofinger A; Petrie JJ; Johnson DW
    Am J Kidney Dis; 2006 May; 47(5):809-14. PubMed ID: 16632019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total body retention and intestinal absorption of orally administered calcium-47 in chronic hemodialysis patients.
    Rubinger D; Ronen M; Schachner E; Czaczkes JW
    Isr J Med Sci; 1980 Mar; 16(3):165-8. PubMed ID: 7390756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impairment of beta 2-adrenoceptor-stimulated potassium uptake in end-stage renal disease.
    Stemmer CL; Perez GO; Oster JR
    J Clin Pharmacol; 1987 Aug; 27(8):628-31. PubMed ID: 2821083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin and mineralocorticoids influence on extrarenal potassium metabolism in chronic hemodialysis patients.
    Vlassopoulos D; Sonikian M; Dardioti V; Pani I; Hadjilouka-Mantaka A; Hadjiconstantinou V
    Ren Fail; 2001 Nov; 23(6):833-42. PubMed ID: 11777323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The regulation of plasma aldosterone in hemodialysis patients].
    Louis F; Zwahlen A; Favre H; Vallotton M
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1882-4. PubMed ID: 7006078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
    Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL
    Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
    Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
    Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.